Clinical Trial Update: Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update focusing on preventing sacituzumab govitecan–related neutropenia in metastatic triple-negative breast cancer; the study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Yeon Hee Park | Conditions: Breast Cancer Metastatic | Phase 2 | Status: RECRUITING